JP4585693B2 - Ii型糖尿病を発現する危険性のnmrによる決定方法 - Google Patents
Ii型糖尿病を発現する危険性のnmrによる決定方法 Download PDFInfo
- Publication number
- JP4585693B2 JP4585693B2 JP2000614054A JP2000614054A JP4585693B2 JP 4585693 B2 JP4585693 B2 JP 4585693B2 JP 2000614054 A JP2000614054 A JP 2000614054A JP 2000614054 A JP2000614054 A JP 2000614054A JP 4585693 B2 JP4585693 B2 JP 4585693B2
- Authority
- JP
- Japan
- Prior art keywords
- glucose
- patient
- nmr
- lipoprotein
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13061299P | 1999-04-22 | 1999-04-22 | |
US60/130,612 | 1999-04-22 | ||
PCT/US2000/010463 WO2000065366A1 (en) | 1999-04-22 | 2000-04-19 | Nmr-method for determining the risk of developing type 2 diabetes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002543392A JP2002543392A (ja) | 2002-12-17 |
JP2002543392A5 JP2002543392A5 (US06573293-20030603-C00009.png) | 2007-06-21 |
JP4585693B2 true JP4585693B2 (ja) | 2010-11-24 |
Family
ID=22445506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000614054A Expired - Fee Related JP4585693B2 (ja) | 1999-04-22 | 2000-04-19 | Ii型糖尿病を発現する危険性のnmrによる決定方法 |
Country Status (9)
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
US20040236673A1 (en) * | 2000-10-17 | 2004-11-25 | Eder Jeff Scott | Collaborative risk transfer system |
CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
CA2445431A1 (en) * | 2001-04-23 | 2002-10-31 | Metabometrix Limited | Methods for the diagnosis and treatment of bone disorders |
US7901873B2 (en) | 2001-04-23 | 2011-03-08 | Tcp Innovations Limited | Methods for the diagnosis and treatment of bone disorders |
US20040142403A1 (en) * | 2001-08-13 | 2004-07-22 | Donald Hetzel | Method of screening for disorders of glucose metabolism |
ATE525635T1 (de) * | 2001-11-13 | 2011-10-15 | Univ California | Ionenmobilitätsanalyse biologischer partikel |
US6873914B2 (en) | 2001-11-21 | 2005-03-29 | Icoria, Inc. | Methods and systems for analyzing complex biological systems |
US6862592B1 (en) * | 2001-12-21 | 2005-03-01 | Adobe Systems Incorporated | Document processing in a cross-platform environment |
EP1329716A1 (en) * | 2002-01-16 | 2003-07-23 | Roche Diagnostics GmbH | Method for screening biological samples for presence of the metabolic syndrome |
US7730063B2 (en) * | 2002-12-10 | 2010-06-01 | Asset Trust, Inc. | Personalized medicine service |
US20070011049A1 (en) * | 2005-07-09 | 2007-01-11 | Eder Jeffrey S | Intelligent, personalized commerce chain |
US7426499B2 (en) * | 2004-11-08 | 2008-09-16 | Asset Trust, Inc. | Search ranking system |
US20080027769A1 (en) * | 2002-09-09 | 2008-01-31 | Jeff Scott Eder | Knowledge based performance management system |
US7243030B2 (en) * | 2002-10-25 | 2007-07-10 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US7722536B2 (en) * | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
US7197427B2 (en) * | 2004-03-31 | 2007-03-27 | Genworth Financial Inc. | Method for risk based testing |
EP2189802B1 (en) * | 2004-04-01 | 2014-05-14 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation biosamples |
US7422224B2 (en) * | 2004-04-13 | 2008-09-09 | Kimir Seatpost | Adjustable bicycle seat post assembly |
US20060010098A1 (en) | 2004-06-04 | 2006-01-12 | Goodnow Timothy T | Diabetes care host-client architecture and data management system |
US7951078B2 (en) * | 2005-02-03 | 2011-05-31 | Maren Theresa Scheuner | Method and apparatus for determining familial risk of disease |
EP1702559B1 (de) | 2005-03-15 | 2008-10-29 | Roche Diagnostics GmbH | Verfahren und System zur Untersuchung des Glucosestoffwechsels |
EP2336782B1 (en) * | 2006-03-24 | 2014-08-27 | Metanomics GmbH | Methods for predicting diabetes type II |
US8498915B2 (en) * | 2006-04-02 | 2013-07-30 | Asset Reliance, Inc. | Data processing framework for financial services |
US8247235B2 (en) | 2007-06-08 | 2012-08-21 | Quest Diagnostics Investments Incorporated | Lipoprotein analysis by differential charged-particle mobility |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US9354200B1 (en) | 2008-08-07 | 2016-05-31 | Quest Diagnostics Investments Incorporated | Detection apparatus for differential-charged particle mobility analyzer |
CA2741034C (en) * | 2008-10-20 | 2021-06-22 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
DE102009026651A1 (de) | 2009-06-02 | 2011-02-17 | Großmann, Kay, Dr. rer. nat. (Chemie) | Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten |
US9250211B2 (en) | 2010-12-30 | 2016-02-02 | Quest Diagnostics Investments Incorporated | Magnetic separation of lipoproteins using dextran sulfate |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
WO2012163361A1 (en) * | 2011-05-31 | 2012-12-06 | Aarhus Universitet | Method and system for identification of physiological imbalance in an animal |
AU2012275478B2 (en) * | 2011-06-30 | 2015-07-23 | Liposcience, Inc. | Quantitative NMR clinical analyzers with automatic NMR temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
US9361429B2 (en) * | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
US20150260631A1 (en) * | 2014-03-17 | 2015-09-17 | Health Diagnostic Laboratory, Inc. | System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions |
DE102014203721B4 (de) * | 2014-02-28 | 2018-12-27 | Bruker Biospin Gmbh | Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe |
US20160109472A1 (en) | 2014-10-21 | 2016-04-21 | Health Diagnostic Laboratory, Inc. | Quantitative molar concentration detection of specific apolipoprotein-containing particles present in bodily fluids by using capillary electrophoresis |
CA2965165A1 (en) | 2014-10-21 | 2016-04-28 | Philip Guadagno | Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer |
EP3213088A1 (en) | 2014-10-27 | 2017-09-06 | True Health IP LLC | Lp(a) subform size identification by capillary isoteachophoresis electrophoresis with laser-induced-fluorescence |
AU2015356643B2 (en) | 2014-12-04 | 2019-01-24 | Novartis Ag | Methods and compositions using Klotho variant polypeptides |
CN111448458A (zh) * | 2017-09-07 | 2020-07-24 | 力保科学公司 | 多参数代谢脆弱性指数评估 |
US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
WO2023239869A1 (en) * | 2022-06-09 | 2023-12-14 | Quest Diagnostics Investments Llc | Quantification of lipoprotein subfractions by ion mobility |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US4933844A (en) * | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
JPH06505089A (ja) | 1989-12-21 | 1994-06-09 | ザ ベス イスラエル ホスピタル アソシエイション | アテローム性動脈硬化症のリスク予知法 |
WO1993003450A1 (en) | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
US5585235A (en) * | 1993-04-13 | 1996-12-17 | Diagnescent Technologies, Inc. | Fluorescent assay and method that corrects for spectral interference |
CA2176005A1 (en) * | 1993-11-08 | 1995-05-18 | Trevor G. Redgrave | Labelled diagnostic compositions and methods of their use |
US5685300A (en) * | 1994-04-01 | 1997-11-11 | Kuenstner; J. Todd | Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy |
US6163154A (en) | 1997-12-23 | 2000-12-19 | Magnetic Diagnostics, Inc. | Small scale NMR spectroscopic apparatus and method |
US6226082B1 (en) | 1998-06-25 | 2001-05-01 | Amira Medical | Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy |
-
2000
- 2000-04-19 CA CA002367820A patent/CA2367820C/en not_active Expired - Fee Related
- 2000-04-19 JP JP2000614054A patent/JP4585693B2/ja not_active Expired - Fee Related
- 2000-04-19 DE DE60026287T patent/DE60026287T2/de not_active Expired - Lifetime
- 2000-04-19 AU AU44693/00A patent/AU4469300A/en not_active Abandoned
- 2000-04-19 AT AT00926111T patent/ATE319105T1/de not_active IP Right Cessation
- 2000-04-19 EP EP00926111A patent/EP1171778B1/en not_active Expired - Lifetime
- 2000-04-19 ES ES00926111T patent/ES2256000T3/es not_active Expired - Lifetime
- 2000-04-19 US US09/550,359 patent/US6518069B1/en not_active Expired - Lifetime
- 2000-04-19 WO PCT/US2000/010463 patent/WO2000065366A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1171778A1 (en) | 2002-01-16 |
ES2256000T3 (es) | 2006-07-16 |
DE60026287D1 (de) | 2006-04-27 |
AU4469300A (en) | 2000-11-10 |
ATE319105T1 (de) | 2006-03-15 |
JP2002543392A (ja) | 2002-12-17 |
US6518069B1 (en) | 2003-02-11 |
EP1171778B1 (en) | 2006-03-01 |
CA2367820C (en) | 2009-12-22 |
DE60026287T2 (de) | 2006-08-17 |
WO2000065366A8 (en) | 2001-03-29 |
CA2367820A1 (en) | 2000-11-02 |
WO2000065366A1 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4585693B2 (ja) | Ii型糖尿病を発現する危険性のnmrによる決定方法 | |
Laske et al. | Innovative diagnostic tools for early detection of Alzheimer's disease | |
Jack Jr et al. | Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease | |
Schwertner et al. | Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease | |
Therriault et al. | Staging of Alzheimer’s disease: past, present, and future perspectives | |
US8386187B2 (en) | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same | |
Savorani et al. | High throughput prediction of chylomicron triglycerides in human plasma by nuclear magnetic resonance and chemometrics | |
US20110004453A1 (en) | Method for prediction of lipoprotein content from nmr data | |
US20180372716A1 (en) | Diagnosing multiple sclerosis | |
Lin et al. | Non/mini-invasive monitoring of diabetes-induced myocardial damage by Fourier transform infrared spectroscopy: Evidence from biofluids | |
Iwao et al. | Differences in the relationship between lipid CHD risk factors and body composition in Caucasians and Japanese | |
WO2006038800A1 (en) | Method for providing a insulin resistance biomarker profile of one or more lipids | |
Shahraki et al. | Waist circumference: a better index of fat location than WHR for predicting lipid profile in overweight/obese Iranian women | |
Hostetter | Screening for dyslipidemia: practice parameter | |
JP2006505789A (ja) | 脱髄の検出 | |
CN117405870B (zh) | 基于血清脂质代谢物构建冠心病患者不稳定斑块表型的预测模型 | |
US20240044826A1 (en) | Metabolic vulnerability analyzed by nmr | |
US6869802B1 (en) | Combined cholesterol and bilirubin tests as risk predictors for coronary artery disease | |
Youn et al. | Association between Large Neutral Amino Acids and Brain Integrity in Middle-Aged Adults at Metabolic Risk | |
Dekker | Verhoeff en | |
Kamarajan et al. | Prediction of brain age in individuals with and at risk for alcohol use disorder using brain morphological features | |
Aguado-Codinaa et al. | Evaluation of the characteristics of the HLC-723G11 for the determination of the HbA1c in the University and Polytechnic Hospital La Fe of Valencia Spain | |
CN109564772A (zh) | 生物学特征分析技术 | |
Hyder | A study on correlation between fasting & post-prandial serum triglycerides and severity of stroke-at a tertiary care hospital |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070417 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070417 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100708 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100820 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100906 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130910 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |